Treatment with IMT-VEGF resulted in reduced scar size, improved angiogenesis, and enhanced cardiac function in animal models of MI, highlighting the potential of targeted delivery strategies using IMT-VEGF for effective MI therapy. This evidence concerns the gene VEGFA and myocardial infarction.